SCHEMBL3138767

SCHEMBL3138767

Clc1ccc([C](c2ccccc2)c2ccccc2Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.54
CES1 P23141 2/20 0.54
ALDH1A1 P00352 2/20 0.50
NR4A1 P22736 1/20 0.50
HPGD P15428 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
SMO Q99835 1/20 0.44
MAPT P10636 2/20 0.44
MGLL Q99685 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
NPC1 O15118 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33952 0.93 ALDH1A1 (0.56) CES2CES1ALDH1A1NR4A1HPGD
SCHEMBL374630 0.89 ALDH1A1 (0.56) CES2CES1ALDH1A1NR4A1HPGD
SCHEMBL8346950 0.84 CES2 (0.65) CES2CES1NR4A1MAPTLMNA
SCHEMBL33953 0.84 CES2 (0.65) CES2CES1NR4A1MAPTLMNA
SCHEMBL9577479 0.83 CYP19A1 (0.46) CES2CES1ALDH1A1NR4A1HPGD
SCHEMBL374631 0.81 SMN1; SMN2 (0.55) CES2CES1ALDH1A1HPGDRAB9A
SCHEMBL4416667 0.78 CES2 (0.62) CES2CES1ALDH1A1HPGDMAPT
SCHEMBL8768011 0.78 SLC6A4 (0.53) CES2CES1NR4A1
4-Chloro-Benzoic Acid SCHEMBL6852257 0.78 ALDH1A1 (0.73) CES2CES1ALDH1A1NR4A1HPGD
SCHEMBL8633789 0.77 CYP1A2 (0.52) CES2CES1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230300-A1 INHIBITORS FOR INHIBITING TUMOR METASTASIS Forschungsverbund Berlin E.V. (DE) 2017-10-18 EP disclosed
WO-2016092069-A1 INHIBITORS FOR INHIBITING TUMOR METASTASIS FORSCHUNGSVERBUND BERLIN E.V. (DE) 2016-06-16 WO disclosed
US-8314215-B2 Mild chemically cleavable linker system THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-11-20 US disclosed
US-20100003735-A1 Mild Chemically Cleavable Linker System THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2010-01-07 US disclosed
WO-2008094205-A2 A MILD CHEMICALLY CLEAVABLE LINKER SYSTEM THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003735-A1 Mild Chemically Cleavable Linker System BTD, SPR, DDO CES2 1529/4885CES1 828/4885ALDH1A1 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.